Comparison of GSK Biologicals' Meningococcal Vaccine (GSK134612) and Licensed MenC-CRM197 Vaccine in Healthy Children

Model scores of the 29,894 trials active now.

Model score 3% for any early termination, 0% for termination due to slow enrollment. Past trials like this one (phase, sponsor type and disease area, started 2008–2016) ended terminated 6% of the time (876 trials).

Finished trial that started 2008–2014: scored by a model trained without any trial from its start year, so its own outcome was never used.

Cumulative chance of ending terminated (red) or completed (green) by each year from its start; it actually ended on 2009-01-08. The rest of the way to 100% is still running.

From the competing-risks survival model (termination vs completion, still-running trials censored), fit to trials that started 2008–2014 and recalibrated to termination rates over 2022–2024, since termination has become more common. Checked on past years, it still ran a little low when the rise continued.

• Wording of the registration (title, summary, criteria) (lowers risk) · Wording Phrases that raised it: protocoldiseasecompletedtime ofpurpose of
  Phrases that lowered it: vaccinesubjectshealthyvaccinationperiod
• Accepts healthy volunteers: Yes (lowers risk) · Who can join
• Sponsor's past termination rate: 3.3% (lowers risk) · Sponsor's track record
• Primary purpose: prevention (lowers risk) · Design
• Trials the sponsor started in the prior 2 years: 544 (raises risk) · Sponsor's track record
• Phase: 3 (lowers risk) · Design
• Has a data monitoring committee: not given (lowers risk) · Design
• Sponsor's past trials: 727 (raises risk) · Sponsor's track record
• Design: parallel (raises risk) · Design
• Minimum age: 2 (lowers risk) · Who can join
• Drug's FAERS reports with a death: 0% (lowers risk) · Drug's FDA history
• Disease area, cancer: No (lowers risk) · Disease area
• Sponsor type: industry (lowers risk) · Sponsor's track record
• Drug's FAERS reports marked serious: 100% (raises risk) · Drug's FDA history
• Blinding: none (lowers risk) · Design
• Keywords listed: 5 (lowers risk) · Design
• Maximum age: 10 (lowers risk) · Who can join
• Disease area, psychiatry: No (lowers risk) · Disease area

Every input that moved this score, largest first: SHAP contributions in log-odds, red raising risk and green lowering it. They describe the model, not causes of termination. Phrases are traced from the text features back to this registration's words, approximately.

• Immunogenicity and Safety Study of GSK Biologicals' Meningococcal Vaccine Given as One Dose to Healthy Subjects Above 56 Years NCT01235975 · started 2010 · scored riskier than 1% of active trials completed
• Co-administration of Meningococcal Vaccine GSK134612 and Pneumococcal Vaccine GSK1024850A vs Individual Administration NCT00758264 · started 2008 · scored riskier than 2% of active trials completed
• Comparison of GSK134612 in Subjects Previously Vaccinated Against Meningococcal Disease Versus Non-vaccinated Subjects NCT00661557 · started 2008 · scored riskier than 2% of active trials completed
• Immunogenicity and Safety Study of GSK Biologicals' Meningococcal Vaccine GSK 134612 Versus Menactra® in Healthy Adolescents/Adults NCT01165242 · started 2010 · scored riskier than 1% of active trials completed
• Immunogenicity and Safety of Meningococcal Vaccine GSK 134612 Versus Mencevax™ ACWY in Healthy 18-25 Year Olds NCT01154088 · started 2010 · scored riskier than 1% of active trials completed

Closest by meaning of the registration text (PubMedBERT embeddings), among finished trials. How they ended is context, not an input to this trial's score.